Kimberly-Clark Corporation completed its acquisition of Kenvue Inc. on Nov. 2, bringing Tylenol and Huggies under one owner as it pursues $2.1 billion in annual synergies.
Under the deal, each Kenvue share was converted into the right to receive $3.50 in cash and 0.14625 shares of Kimberly-Clark common stock. Kenvue shares stopped trading on the New York Stock Exchange at the market open.
Kimberly-Clark expects about $2.1 billion in annual run-rate synergies. Its estimate includes roughly $1.9 billion in cost savings within three years and about $500 million in additional profit from revenue growth within four years, partly offset by approximately $300 million in reinvestment. These are management projections. Kimberly-Clark says it plans to use its “Powering Care” strategy to develop products, strengthen brands and improve sales execution.
When it announced the agreement in 2025, Kimberly-Clark said it expected the deal to increase adjusted earnings per share by the second year after closing. Its Nov. 2 announcement reaffirmed the synergy estimates but did not repeat that earnings timetable. Chairman and CEO Mike Hsu said the company would move “with speed and purpose” to realize the combination’s potential.
Kenvue’s final reported quarter before the deal closed provides a pre-acquisition baseline. For the three months ended Sept. 27, net sales were $3.886 billion, up 3.2% from a year earlier, while organic sales rose 2.9%. Organic sales increased 5.4% in Self Care and 2.5% in Essential Health, but declined 0.5% in Skin Health and Beauty. Kenvue said it was not providing forward guidance because of the pending transaction.
Kimberly-Clark closed a $4.9 billion senior unsecured notes offering on Oct. 29. It said the proceeds, together with cash on hand and/or commercial-paper borrowings, would fund the cash payment and related expenses. The company’s closing announcement also listed increased indebtedness and its ability to reduce debt among the deal’s risks.
Kenvue’s quarterly filing said the Second Circuit Court of Appeals vacated a district court judgment in July and sent the case back for further proceedings. The filing said Kenvue could not reasonably estimate the likelihood or amount of potential liability. The claims allege an association between prenatal acetaminophen exposure and autism or ADHD; in September 2025, the Food and Drug Administration said a causal relationship had not been established.
Kimberly-Clark is scheduled to report third-quarter results Thursday, Nov. 5, at about 6:30 a.m. ET, followed by an analyst Q&A at 8 a.m. ET. The quarter ended Sept. 30, before the acquisition closed.
